Private equity investors in health care and life sciences are accustomed to navigating a complex and shifting regulatory and policy environment, and 2025 put those capabilities into sharp focus. Under the Biden administration, there was a slowdown in the velocity of private equity investments into the health care space as the scrutiny of deals intensified and authorities took an aggressive stance. With the arrival of the new president, that challenge has not completely disappeared as investors come to terms with broader federal policy changes. At the same time, funds are also responding to positive signals from the administration.
Read the full article: 2026 Perspectives in Private Equity: Health Care & Life Sciences //
Source: https://www.lexology.com/library/detail.aspx?g=fca131da-72db-4f4b-9219-72727dc12163